QuidelOrtho (QDEL) falls after weak Q1 as respiratory demand, China disruption weigh

QuidelOrtho Corp. (QDEL) reported first-quarter headwinds tied to a milder respiratory illness season and disruption in China from expected diagnostic pricing changes, pressuring results and investor sentiment. Shares traded at $10.12 on May 15, 2026, down from $11.66 before the earnings release. CEO Brian Blaser said influenza-like illness visits fell about 30% from the prior year, weakening demand for respiratory diagnostics. Management also cited macroeconomic and geopolitical pressures, including delayed orders in the Middle East. Investors are watching whether Chinese distributor orders stabilize, how national in vitro diagnostic pricing guidelines develop, and whether new molecular and cardiac diagnostic platforms, including Lex Diagnostics and a high-sensitivity troponin assay, gain traction. Cost cuts and facility consolidation remain key execution points for restoring financial momentum.